[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575849":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":59,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HCC patients",null,"Patients with advanced HCC undergoing immunotherapy",[13],"Drug: Immunochemotherapy combined with antiangiogenic",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Immunochemotherapy combined with antiangiogenic",[9],[20],{"name":21,"affiliation":5,"role":22},"Laura Gramantieri","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Laura Gramantieri, MD","CONTACT","0512142579","laura.gramantieri@aosp.bo.it",[30],{"facility":31,"status":32,"city":33,"state":21,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"IRCCS-Azienda Ospedaliero-Universitaria di Bologna","RECRUITING","Bologna","40138","Italy",{"type":37,"coordinates":38},"Point",[39,40],11.33875,44.49381,{"lat":40,"lon":39},[43],{"name":25,"role":26,"phone":44,"phoneExt":10,"email":28},"+390512142214",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100575849",false,"NCT06777628","Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma","Immunophenotype of Peripheral Blood Mononuclear Cells to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma","Immunecheck","Inclusion Criteria:\n\n* age ≥ 18 years\n* diagnosis of HCC\n* execution of laboratory tests and subsequent treatments and follow-up at our center.\n* obtained written informed consent to the study participation\n\nExclusion Criteria:\n\n* immune-related concomitant diseases\n* HIV infection","ALL","18 Years",{"count":57,"type":58},100,"ESTIMATED","3 Years","OBSERVATIONAL","The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for:\n\n* predicting response to immune-therapeutic regimens in HCC in the early phase of treatment,\n* to rule out pseudo-progression,\n* to early predict the escape from effectiveness of treatment.",[63],"Liver Cancer, Adult",[65,9,66],"immunophenotype","immunotherapy","2025-01-14",{"date":69,"type":70},"2025-01-16","ACTUAL",{"date":72,"type":70},"2024-09-15",{"date":74,"type":58},"2028-10-15",{"name":5,"class":6},1]